Stéphane Bancel
Showing 1–2 of 2 transcripts.
- a16z39 min
Inside Moderna’s Biggest mRNA Test Since COVID
Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismoran, successfully met primary and secondary endpoints in a Phase 3 melanoma trial, demonstrating superior recurrence-free survival compared to the current standard of care. This breakthrough treatment combines a patient-specific mRNA vaccine with Merck's Keytruda to target unique tumor antigens, offering a synthetic manufacturing solution that can produce individualized doses within approximately 42 days. Building on these results, the companies plan to file for FDA approval with the goal of patient availability by 2027 while expanding clinical trials to lung, kidney, and bladder cancers.
- Goldman Sachs1h 22m
A Coronavirus Update with Leading Health Experts and Business Leaders
Sharmin Mossavar-Rahmani, Dr. Thomas Schinecker, Steve Rusckowski, Dr. Leonard Schleifer, Stéphane Bancel, Pablo Tebas, Peter Slavin, Dr. Barry Bloom, Sharmeen Mosavar-Rahmani
Hosted by Goldman Sachs on March 20, 2020, industry leaders including Regeneron's Dr. Leonard Schleifer, Moderna's Stefan Bancel, and Quest Diagnostics executives detailed rapid advancements in diagnostic scaling, therapeutic trials, and vaccine development. The panel highlighted that while testing capacity is projected to meet demand within weeks, critical bottlenecks in PPE and supply chains persist, prompting urgent calls for Defense Production Act mobilization to protect healthcare workers. Simultaneously, experts outlined aggressive timelines for Moderna's mRNA vaccine reaching healthcare workers by late 2020 and emphasized that sustainable economic recovery relies on serologic testing and strict social distancing to prevent a predicted second wave.